dipyridamole has been researched along with Gastric Diseases in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirsh, J | 1 |
| Salzman, EW | 1 |
| Harker, L | 1 |
| Fuster, V | 1 |
| Dalen, JE | 1 |
| Cairns, JA | 1 |
| Collins, R | 1 |
1 review available for dipyridamole and Gastric Diseases
| Article | Year |
|---|---|
Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects.
Topics: Aspirin; Blood Platelets; Dipyridamole; Epoprostenol; Gastrointestinal Hemorrhage; Humans; Platelet | 1989 |